About Neogene Therapeutics

Neogene Therapeutics is a global, preclinical stage biotechnology company pioneering the development of next generation, fully individualized engineered T cell therapies for a broad spectrum of cancers.

While engineered T cell therapies have transformed the treatment paradigm for patients with hematologic malignancies, effective T cell therapy is limited for patients with solid cancers. To truly revolutionize patient outcomes, we need a new approach to effectively treat and potentially cure solid cancers. We believe that through a fully individualized approach using patient-specific TCRs to target neoantigens, engineered T cell therapy can become broadly accessible to these patients.

Our proprietary neoantigen T cell receptor (TCR) discovery and T cell engineering platform identifies TCR genes with specificity for neoantigens – found exclusively on cancer cells as a result of cancer-associated DNA mutations. Neogene aims to overcome the limitations of current T cell therapies by using these neoantigen specific TCRs in fully individualized engineered T cell therapies.